Literature DB >> 14742230

Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine.

Lieven J Stuyver1, Tamara R McBrayer, Tony Whitaker, Phillip M Tharnish, Mangala Ramesh, Stefania Lostia, Leanne Cartee, Junxing Shi, Ann Hobbs, Raymond F Schinazi, Kyoichi A Watanabe, Michael J Otto.   

Abstract

2'-Deoxy-2'-fluorocytidine (FdC) is a potent inhibitor of the hepatitis C virus RNA replicon in culture, and FdC-5'-triphosphate is an effective inhibitor of the NS5B polymerase. Dynamic profiling of cell growth in an antiviral assay showed that FdC caused cytostasis due to an S-phase arrest. These observations demonstrate that FdC treatment is affecting both a viral target and a cellular target.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14742230      PMCID： PMC321524          DOI： 10.1128/AAC.48.2.651-654.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.

Authors:  Lieven J Stuyver; Tony Whitaker; Tamara R McBrayer; Brenda I Hernandez-Santiago; Stefania Lostia; Phillip M Tharnish; Mangala Ramesh; Chung K Chu; Robert Jordan; Junxing Shi; Suguna Rachakonda; Kyoichi A Watanabe; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  Studies on the growth inhibition and metabolism of 2'-deoxy-2'-fluorocytidine in cultured human lymphoblasts.

Authors:  L W Brox; G A LePage; S S Hendler; D H Shannahoff
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

3.  The effect of 2'-fluoro-2'-deoxycytidine on herpes virus growth.

Authors:  F Wohlrab; A T Jamieson; J Hay; R Mengel; W Guschlbauer
Journal:  Biochim Biophys Acta       Date:  1985-03-20

4.  Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents.

Authors:  Lieven J Stuyver; Stefania Lostia; Steven E Patterson; Jeremy L Clark; Kyoichi A Watanabe; Michael J Otto; Krzysztof W Pankiewicz
Journal:  Antivir Chem Chemother       Date:  2002-11

5.  In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Authors:  Caterina Trozzi; Linda Bartholomew; Alessandra Ceccacci; Gabriella Biasiol; Laura Pacini; Sergio Altamura; Frank Narjes; Ester Muraglia; Giacomo Paonessa; Uwe Koch; Raffaele De Francesco; Christian Steinkuhler; Giovanni Migliaccio
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.

Authors:  Arnim Pause; George Kukolj; Murray Bailey; Martine Brault; Florence Dô; Ted Halmos; Lisette Lagacé; Roger Maurice; Martin Marquis; Ginette McKercher; Charles Pellerin; Louise Pilote; Diane Thibeault; Daniel Lamarre
Journal:  J Biol Chem       Date:  2003-03-19       Impact factor: 5.157

7.  Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons.

Authors:  I Wayne Cheney; Vicky C H Lai; Weidong Zhong; Tessa Brodhag; Shannon Dempsey; Charmaine Lim; Zhi Hong; Johnson Y N Lau; Robert C Tam
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 8.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

Authors:  W Plunkett; P Huang; Y Z Xu; V Heinemann; R Grunewald; V Gandhi
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

9.  Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites.

Authors:  Lieven J Stuyver; Tamara R McBrayer; Phillip M Tharnish; Abdalla E A Hassan; Chung K Chu; Krzysztof W Pankiewicz; Kyochi A Watanabe; Raymond F Schinazi; Michael J Otto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs.

Authors:  Steven S Carroll; Joanne E Tomassini; Michele Bosserman; Krista Getty; Mark W Stahlhut; Anne B Eldrup; Balkrishen Bhat; Dawn Hall; Amy L Simcoe; Robert LaFemina; Carrie A Rutkowski; Bohdan Wolanski; Zhucheng Yang; Giovanni Migliaccio; Raffaele De Francesco; Lawrence C Kuo; Malcolm MacCoss; David B Olsen
Journal:  J Biol Chem       Date:  2003-01-27       Impact factor: 5.157
View more
  20 in total

1.  Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus.

Authors:  Stephen R Welch; Florine E M Scholte; Mike Flint; Payel Chatterjee; Stuart T Nichol; Éric Bergeron; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2017-10-09       Impact factor: 5.970

2.  In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Authors:  Yohichi Kumaki; Craig W Day; Donald F Smee; John D Morrey; Dale L Barnard
Journal:  Antiviral Res       Date:  2011-09-08       Impact factor: 5.970

3.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

Review 4.  Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides.

Authors:  Jerome Deval
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.

Authors:  Amy Fung; Zhinan Jin; Natalia Dyatkina; Guangyi Wang; Leo Beigelman; Jerome Deval
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

Review 6.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

7.  Fluorinated Nucleosides: Synthesis and Biological Implication.

Authors:  Peng Liu; Ashoke Sharon; Chung K Chu
Journal:  J Fluor Chem       Date:  2008-09       Impact factor: 2.050

8.  Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides.

Authors:  Jamie J Arnold; Suresh D Sharma; Joy Y Feng; Adrian S Ray; Eric D Smidansky; Maria L Kireeva; Aesop Cho; Jason Perry; Jennifer E Vela; Yeojin Park; Yili Xu; Yang Tian; Darius Babusis; Ona Barauskus; Blake R Peterson; Averell Gnatt; Mikhail Kashlev; Weidong Zhong; Craig E Cameron
Journal:  PLoS Pathog       Date:  2012-11-15       Impact factor: 6.823

9.  Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes.

Authors:  Julie A Heck; Angela M I Lam; Nirupama Narayanan; David N Frick
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

10.  Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.

Authors:  Steven W Ludmerer; Donald J Graham; Evelyn Boots; Edward M Murray; Amy Simcoe; Eric J Markel; Jay A Grobler; Osvaldo A Flores; David B Olsen; Daria J Hazuda; Robert L LaFemina
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.